Volume 26, Issue 3 (10-2024)                   yafte 2024, 26(3): 45-59 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Hasanvand A, Ghiasvand A, Nourmohammadi M, Hatami F, Haghighatian Z, Mokhayeri Y et al . Investigating the analgesic effects of Adalimumab in chronic constriction injury (CCI) experimental pain model in rats. yafte 2024; 26 (3) :45-59
URL: http://yafte.lums.ac.ir/article-1-3746-en.html
Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran & Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran
Abstract:   (518 Views)
Background: Neuropathic pain is one of the most important chronic and pathological problems that can cause disruptions in human life. Some studies indicated that the release of inflammatory cytokines and increased oxidative activity can increase nerve damage. Adalimumab is a human anti-monoclonal drug that can cause therapeutic effects in different diseases. The present study aimed to investigate the analgesic effects of adalimumab in the chronic constriction injury (CCI) experimental pain model in rats.
Materials and Methods: A total of 20 male Wistar rats were utilized in this study and were randomly assigned to four groups: the first group served as the control, the second group underwent CCI, the third group received CCI in conjunction with adalimumab (5 mg/kg), and the fourth group received CCI with adalimumab (10 mg/kg). Behavioral assessments were conducted 4, 7, and 14 days post-CCI induction. The spinal cords were extracted after these assessments, and the supernatants were analyzed for inflammatory and oxidative enzymes. Data analysis was performed using Prism GraphPad statistical software.
Results: The analysis of the obtained data indicated that the injection of adalimumab in the third and fourth groups decreased the activity of inflammatory cytokines, such as TNF-α, IL-6, and CRP. In addition, it decreased the activity of MDA and increased the SOD and CAT enzymes. Moreover, adalimumab significantly improved the outcomes of thermal allodynia, mechanical allodynia, and thermal hyperalgesia in the CCI rats treated with this medication.
Conclusion: The administration of adalimumab can be used to treat or reduce neuropathic pain with its anti-inflammatory and antioxidant activity, along with neuroprotective effects.
 
Full-Text [PDF 668 kb]   (270 Downloads)    
Type of Study: Research |
Received: 2024/06/25 | Accepted: 2024/10/5 | Published: 2024/10/1

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Yafteh

Designed & Developed by : Yektaweb